The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study
Open accessAbstract
BACKGROUND: Medullary thyroid carcinoma (MTC) is a well-differentiated thyroid tumor that maintains the typical features of C cells. An advanced stage and the presence of lymph node metastases at diagnosis have been demonstrated to be the most important bad prognostic factors. Somatic RET mutations have been found in 40-50% of MTCs. Although a relationship between somatic mutations and bad prognosis has been described, data are controversial and have been performed in small series with short-term follow ups. The aim of this study was to verify the prognostic value of somatic RET mutations in a large series of MTCs with a long follow up. METHODS: We studied 100 sporadic MTC patients with a 10.2 yr mean follow-up. RET gene exons 10-11 and 13-16 were analyzed. The correlation between the presence/absence of a somatic RET mutation, clinical/pathological features, and outcome of MTC patients was evaluated. RESULTS: A somatic RET mutation was found in 43 of 100 (43%) sporadic MTCs. The most frequent mutation (34 of 43, 79%) was M918T. RET mutation occurrence was more frequent in larger tumors (P=0.03), and in MTC with node and distant metastases (P<0.0001 and P=0.02, respectively), thus, a significant correlation was found with a more advanced stage at diagnosis (P=0.004). A worse outcome was also significantly correlated with the presence of a somatic RET mutation (P=0.002). Among all prognostic factors found to be correlated with a worse outcome, at multivariate analysis only the advanced stage at diagnosis and the presence of a RET mutation showed an independent correlation (P<0.0001 and P=0.01, respectively). Finally, the survival curves of MTC patients showed a significantly lower percentage of surviving patients in the group with RET mutations (P=0.006). CONCLUSIONS: We demonstrated that the presence of a somatic RET mutation correlates with a worse outcome of MTC patients, not only for the highest probability to have persistence of the disease, but also for a lower survival rate in a long-term follow up. More interestingly, the presence of a somatic RET mutation correlates with the presence of lymph node metastases at diagnosis, which is a known bad prognostic factor for the definitive cure of MTC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B
Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., et al. (1995) · Science · doi:10.1126/science.7824936 · Cited by 841
Modigliani, E., Cohen, R., Campos, J., Conte‐Devolx, B., Maes, B., Boneu, A., Schlumberger, M., Bigorgne, J., Dumontier, P., Leclerc, L., et al. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00392.x · Cited by 570
Eng, C., SmIth, D. P., MullIgan, L. M., Nagal, M. A., Healey, C. S., Ponder, M. A., Gardner, E., Scheumann, G. F. W., Jackson, C. E., Tunnacllffe, A., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.2.237 · Cited by 537
Elisei, R., Bottici, V., Luchetti, F., Di Coscio, G., Romei, C., Grasso, L., Miccoli, P., Iacconi, P., Basolo, F., Pinchera, A., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030550 · Cited by 537
Self-citationSomatic mutations in the RET proto‐oncogene in sporadic medullary thyroid carcinoma
Marsh, D. J., Learoyd, D. L., Andrew, S. D., Krishnan, L., Pojer, R., Richardson, A., Delbridge, L., Eng, C., & Robinson, B. G. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.681503.x · Cited by 279
The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid.
Melvin, K. E., & Tashjian, A. H. (1968) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.59.4.1216 · Cited by 171
Surgical Strategy for the Treatment of Medullary Thyroid Carcinoma
Fleming, J. B., Lee, J. E., Bouvet, M., Schultz, P. N., Sherman, S. I., Sellin, R. V., Friend, K. E., Burgess, M. A., Cote, G. J., Gagel, R. F., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199911000-00013 · Cited by 152
Schilling, T., B�rck, J., Sinn, H., Clemens, A., Otto, H. F., H�ppner, W., Herfarth, C. H., Ziegler, R., Schwab, M., & Raue, F. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010120)95:1<62::aid-ijc1011>3.0.co;2-1 · Cited by 148
Iwashita, T., Kato, M., Murakami, H., Asai, N., Ishiguro, Y., Ito, S., Iwata, Y., Kawai, K., Asai, M., Kurokawa, K., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202742 · Cited by 120
Cited by
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
Self-citationWells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Self-citationMedullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Kloos (Chair), R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., Moley, J. F., Pacini, F., Ringel, M. D., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0403 · Cited by 1,357
Self-citationCabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Self-citationTumour heterogeneity in the clinic
Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013) · Nature · doi:10.1038/nature12627 · Cited by 1,211
Rindi, G., Klimstra, D. S., Abedi-Ardekani, B., Asa, S. L., Bosman, F. T., Brambilla, E., Busam, K. J., de Krijger, R. R., Dietel, M., El-Naggar, A. K., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0110-y · Cited by 1,163
Biologic and Clinical Perspectives on Thyroid Cancer
Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 990
Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y. (2014) · Journal of Thyroid Research · doi:10.1155/2014/638747 · Cited by 475
Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00120-0 · Cited by 366
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
Romei, C., Ciampi, R., & Elisei, R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.11 · Cited by 352
Self-citationSchlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7815 · Cited by 340
Self-citationRET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Kato, S., Subbiah, V., Marchlik, E., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1679 · Cited by 282
for the German Societies of General and Visceral Surgery; Endocrinology; Nuclear Medicine; Pathology; Radiooncology; Oncological Hematology; and the German Thyroid Cancer Patient Support Organization Ohne Schilddrüse leben e.V., Dralle, H., Musholt, T. J., Schabram, J., Steinmüller, T., Frilling, A., Simon, D., Goretzki, P. E., Niederle, B., Scheuba, C., et al. (2013) · Langenbeck's Archives of Surgery · doi:10.1007/s00423-013-1057-6 · Cited by 279
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Subbiah, V., Yang, D., Velcheti, V., Drilon, A., & Meric-Bernstam, F. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02551 · Cited by 258
Agrawal, N., Jiao, Y., Sausen, M., Leary, R., Bettegowda, C., Roberts, N. J., Bhan, S., Ho, A. S., Khan, Z., Bishop, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2703 · Cited by 255
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
Pach, D., Sowa-Staszczak, A., Jabrocka-Hybel, A., Stefańska, A., Tomaszuk, M., Mikołajczak, R., Janota, B., Trofimiuk-Müldner, M., Przybylik-Mazurek, E., & Hubalewska-Dydejczyk, A. (2013) · International Journal of Endocrinology · doi:10.1155/2013/384508 · Cited by 25
Metadata
- Authors
- Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E., Agate, L., Vivaldi, A., Faviana, P., Basolo, F., Miccoli, P., Berti, P., Pacini, F., & Pinchera, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-03-01
- Volume
- 93
- Issue
- 3
- Pages
- 682-687
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2060543813
- Cited by
- 531
- References
- 13
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.